CollPlant Stock Plummets 25% Amid Mixed Reaction to Dermal Filler Trial Results

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-30 15:01:02

BTCCSquare news:

CollPlant Biotechnologies saw its shares tumble 25% on Tuesday despite positive results from a non-clinical trial of its innovative photocurable dermal filler. The company's rhCollagen-based gel, designed to harden under light exposure for long-lasting aesthetic results, failed to impress investors despite management's enthusiasm.

CEO Yehiel Tal touted the technology's potential to redefine aesthetic medicine standards, emphasizing its dual capability for immediate contouring and natural tissue integration. The market's bearish response contrasts sharply with CollPlant's plans to scale production ahead of clinical trials that will determine the product's safety and efficacy.

By:

Log in to Reply

Digitap’s TAP Presale Gains Momentum Amid Utility-Driven Demand

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.